Table 2.

Proton-pump inhibitors use in patients with Torsades de Pointes.

Patients under active treatment with PPIs, n	28/48(58%)
Specific PPI used, n
Pantoprazole	18/28(64%)
Lansoprazole	6/28(21%)
Omeprazole	3/28(11%)
Esomeprazole	1/28(4%)
Treatment duration*
Extended therapy (>2 weeks), n	16/25(64%)
Not extended therapy (<2 weeks), n	9/25(36%)
Daily dose, mg†
Pantoprazole	33.3 ± 9.7
Lansoprazole	27.5 ± 6.1
Omeprazole	26.7 ± 11.5
Esomeprazole	20
Route of administration, n†
Oral	22/28(79%)
Intravenous	6/28(21%)

Except where indicated otherwise, values are expressed as mean ± standard deviation.

^*Data missing in 3 out of 28 patients.

^†At the moment of TdP occurrence.